Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Laura Prendergast
STIF

Laura Prendergast

Stifel Nicolaus
Wall Street Analyst
★★☆☆☆
#2830
on 13Foresight · ranked by our own returns
32%
Success Rate
-7.2%
Average Return
13 of 40 calls profitable · +10.8% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 32% of Laura Prendergast's ratings turned a profit when each position was held for 1 year — averaging -7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 1 Hold 0 Sell
Laura's Stock Coverage 15 ratings · 2026-11-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ORIC
Oric Pharmaceuticals
 Oct 29, 2026 BUY Strong Buy
+160.3% avg upside
21 analysts
$18.00
94.85% Upside
 -2.5% ·
COGT
Cogent Biosciences
 Oct 27, 2026 BUY Strong Buy
+24.4% avg upside
26 analysts
$45.00
44.99% Upside
 -8.6% ·
IMTX
Immatics
 Oct 26, 2026 BUY Strong Buy
+144.7% avg upside
16 analysts
$15.00
108.42% Upside
 -11.1% ·
IDYA
IDEAYA Biosciences
 Oct 26, 2026 BUY Strong Buy
+48.3% avg upside
31 analysts
$48.00
50.26% Upside
 -0.5% ·
TNGX
Tango Therapeutics
 Oct 23, 2026 BUY Strong Buy
+76.4% avg upside
16 analysts
$55.00
142.06% Upside
 +7.6% ·
RVMD
Revolution Medicines
 Oct 08, 2026 BUY Strong Buy
+8.2% avg upside
36 analysts
 — -5.9% ·
FHTX
Foghorn Therapeutics
 Oct 01, 2026 BUY Buy
+336.7% avg upside
17 analysts
$5.00
140.39% Upside
 -30.1% ·
OLMA
Olema Pharmaceuticals
 Sep 14, 2026 BUY Strong Buy
+401.3% avg upside
16 analysts
$30.00
328.48% Upside
 -24.6% ·
BBOT
BridgeBio Oncology Therapeutics
 Sep 09, 2026 BUY Strong Buy
+714.3% avg upside
11 analysts
$15.00
472.54% Upside
 -64.9% ·
ERAS
Erasca
 Aug 17, 2026 BUY Strong Buy
+46.4% avg upside
14 analysts
$30.00
109.03% Upside
 -13.0% ·
STRO
Sutro Biopharma
 Aug 17, 2026 BUY Strong Buy
+357.6% avg upside
22 analysts
$48.00
427.38% Upside
 -53.9% ·
BDTX
Black Diamond Therapeutics
 Aug 06, 2026 BUY Strong Buy
+703.4% avg upside
12 analysts
$8.00
349.46% Upside
 -3.1% ·
HLIT
Harmonic
 Jul 29, 2025 BUY Buy
+29.9% avg upside
14 analysts
$12.00
17.31% Upside
 +21.6% ·
XLO
Xilio Therapeutics
 Feb 13, 2025 BUY Strong Buy
+114.2% avg upside
7 analysts
$4.00
50.24% Downside
 -55.0% ·
NKTX
Nkarta
 Aug 14, 2024 BUY Strong Buy
+1080.5% avg upside
16 analysts
$16.00
925.57% Upside
 -57.1% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Laura Prendergast — Frequently Asked Questions
How accurate are Laura Prendergast's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Laura's ratings were profitable over a one-year hold, with an average return of -7.3% per rating, or -8.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Laura ranked on 13Foresight?
Laura Prendergast is currently ranked #2830 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Laura cover?
Laura most recently has ratings on ORIC, COGT, IMTX, IDYA, TNGX, RVMD, FHTX, OLMA, BBOT, ERAS, STRO, BDTX and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.